Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Doxorubicin induced cardiomyopathy is the most common and serious side effect associated with
doxorubicin treatment in cancer patients receiving doxorubicin. Studies have been shown that
Empagliflozin can reduce cardiovascular mortality and hospitalization for heart failure in
patients with heart failure with or without diabetes and current clinical trials indicate
that SGLT2 inhibitors protect against heart failure outcomes and can reduce cardiac
remodeling even in patients without diabetes. Empagliflozin had beneficial effects on the
outcome of the cardiomyopathy and also has anti-tumor activity in animal studies, but
clinical studies are still lacking. We are going to investigate the cardioprotective effect
of Empagliflozin against doxorubicin induced cardiomyopathy.
Objective:
- Evaluate the prophylactic effect of using Empagliflozin "a selective inhibitor of the
sodium glucose co-transporter 2 (SGLT2)" against doxorubicin induced cardiotoxicity in
patients receiving doxorubicin-based chemotherapy.
- Monitor the safety of adding empagliflozin to doxorubicin-based chemotherapy.